The global women health therapeutics market is anticipated to grow at a considerable CAGR of 5.3% during the forecast period. The key factors contributing to the growth of the market include a rising prevalence of chronic diseases such as cancer and others coupled with lifestyle-associated disorders in women. Moreover, an increase in investment by key market players to fulfill the disease treatment demand in areas such as infection, pregnancy-related complications, and cancers, is further propelling the market growth. According to the World Health Organization (WHO), one in every four couples has been affected by infertility in emerging economies, such as China. Under the age of 60, female infertility is ranked 5th highest serious disability across the globe. Hence, government and private companies have increased their investment to improve women's healthcare for infertility, and cancers prevailing such as cervical, ovarian, breast, and uterine cancer. According to WHO, in 2020, there were 2.3 million women diagnosed with breast cancer and 685 000 deaths globally. As of the end of 2020, there were 7.8 million women alive who were diagnosed with breast cancer.

Impact of COVID-19 Pandemic on Global Women Health Therapeutics Market

During the COVID-19 pandemic, several markets struggle at the beginning of 2020. Similarly, the women health therapeutics market also faced a decline as the lockdown was implemented across the globe. According to the United Nations Population Fund, women in 115 low- and middle-income countries experienced an average of 3.6 months of disruption due to a lack of access to family planning services, resulting in an estimated 7 million unwanted pregnancies. The pandemic damaged maternal health care in Nepal, increasing maternal mortality, with 258 women dying as a result of pregnancy or childbirth between March 2020 and June 2021, compared to 51 maternal deaths the year before COVID-19. However, market players made a lot of changes to their businesses with innovative ideas, which constrained their anticipated loss.

Segmental Outlook 

The global women health therapeutics market is segmented based on the type and end-user. Based on type, the market is classified into infection, pregnancy, and oncology. The oncology segment is further augmented into cervical cancer, uterine cancer, ovarian cancer, and vaginal & vular. Based on the end-user, the market is segmented into hospitals and clinics, and ambulatory centers. The above-mentioned segments can be customized as per the requirements. Among the type segment, oncology is expected to hold a prominent share in the market during the forecast period, owing to the rising incidences of cancer across the globe. 

Global Women Health Therapeutics  Market Share by Type, 2021 (%)

The Oncology Segment is Expected to Hold a Prominent Share in the Global Women Health Therapeutics Market

The oncology segment is expected to hold a prominent share in the global women health therapeutics market over the forecast period. Some factors propelling the market growth include the high incidence of infectious diseases, increasing drug approvals, and the availability of diagnostic tests and treatments. Further, the rising incidence of ovarian cancer is anticipated to witness considerable growth in the market. According to Cancer Research Institute, around 300,000 people each year are diagnosed with ovarian cancer which causes approximately 180,000 deaths. Additionally, in 2021, ovarian cancer diagnosed in approximately 21,000 people and cause about 14,000 deaths in the US. For instance, in November 2021 Cytalux (pafolacianine), an imaging medication designed to help surgeons locate ovarian cancer lesions, was approved by the US Food and Drug Administration. The medicine is intended to boost the ability to detect more ovarian malignant tissue following surgery, which is generally difficult to detect. Cytalux is used to help locate malignant tumours during surgery in adult patients with ovarian cancer. The medication is a diagnostic agent that is given as an intravenous injection before surgery.

Regional Outlooks

The global women health therapeutics market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). The market can be analyzed for a particular region or country level as per the requirement. 

Global Women Health Therapeutics Market Growth, by Region 2022-2028

therapeutics-market-growth-by-region.png" alt="Global Women Health Therapeutics Market Growth, by Region" title="Global Women Health Therapeutics Market" class="img-fluid">

The Asia-Pacific Region Anticipating to Hold a Prominent Share in the Global Women Health Therapeutics Market

Asia-Pacific is expected to be at the forefront of the market owing to its growing economy and increasing population. With the presence of emerging countries such as China, India, Korea, Japan, and others, the region is the most populous and growing across the globe. Further, in countries including India and China, significant government measures to promote gender equality have increased the female population, which in turn increases the participation of women in the workforce coupled with increased women's disposable income. Thus, such factors have gained traction in the government of the countries to provide improved and enhanced healthcare facilities across the region, especially for women. For instance, in September 2021, the Government of China pledged to reduce the prices of diagnoses of chronic diseases to decrease the burden on the people.

Market Players Outlook

The major companies serving the global women health therapeutics market include Novartis AG, Abbott Laboratories, Inc., Pfizer Inc., Eli Lilly and Co., Bayer AG, Merck KGaA, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in December 2021, F. Hoffmann-La Roche introduced its PIK3CA Mutation Test for patients who were diagnosed with breast cancer in those countries which accepted the CE mark.

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global women health therapeutics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.